New anti-amyloid therapies are transforming the treatment landscape for Alzheimer's disease. In this episode of ISTAART Voices, Dr. Gregory Jicha and Dr. Peter Nelson compare emerging Alzheimer's treatments to biologics used in cancer and other diseases. Their insightful analysis highlights the significance of new disease-modifying therapies, further illustrating why choices and access to treatment are crucial for individuals living with Alzheimer's disease.Special thanks to ISTAART Ambassador Shloka Dhareshwar for her contributions to the production of this episode of ISTAART Voices.LinksShow page: alz.org/ISTAARTpodcast ISTAART: alz.org/ISTAART Featured paper: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.12500?utm_source=podcast&utm_medium=newsletter&utm_campaign=IVS1_GJPN&utm_id=ISTAARTVoicesGregory A. Jicha: https://medicine.uky.edu/users/gajich2Peter T. Nelson: https://medicine.uky.edu/users/pnels2Clinicans’ Resources: www.alz.org/ISTAARTcliniciansALZ-NET: https://www.alz-net.org/ Podcast CMEs: www.alz.org/ISTAARTpodcastCMEAlzheimer's Association International Conference® 2025 (AAIC®): alz.org/AAICAlzheimer's Association Scientific Meetings: alz.org/scientificmeetings Alzheimer's Association Journal Family: alz.org/journals Social: #ISTAART @ISTAART The views and opinions expressed in this podcast are solely those of the guests and do not necessarily reflect those of the Alzheimer's Association. The Alzheimer's Association does not endorse any external product or service. This podcast is for informational purposes and is not intended to provide medical advice, please consult your physician. Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios